Marianna Stamou

Director, Project Toxicologist AstraZeneca

Marianna Stamou is a Director Project Toxicologist at AstraZeneca, where since 2017 she has been leading the nonclinical safety strategy of programs across stages of development and modalities, including small molecules, ADCs & RLTs. She’s been an American Board of Toxicology Diplomate since 2021, and has authored 23 peer-reviewed publications and one book chapter. She received her PhD in Pharmacology & Toxicology from the University of California, Davis, and was a postdoctoral fellow at the ETH Zurich Chair of Toxicology in Switzerland. Marianna also holds an MBA, an MSc in Pharmaceutical Production and Quality Control, and an MEng in Chemical Engineering.

Seminars

Thursday 25th February 2027
Defining the Non-Clinical Safety Strategy for Next-Generation Radiopharmaceuticals
4:30 pm
  • Navigate differences in non-clinical safety requirements across regulatory regions to understand what evidence is needed to progress towards FIH
  • Tailor the safety strategy to the target, modality, and radioconjugate profile, rather than applying a one-size-fits-all toxicology package
  • Identify the remaining safety uncertainties after IND-enabling studies and determine where additional evidence is needed to better predict clinical risk
Marianna Stamou, Speaker at 3rd TRP Target Selection & Drug Design Summit